000 01844cam a2200349 a 4500
003 EG-GiCUC
005 20250223030742.0
008 130120s2012 ua d f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.19.04.Ph.D.2012.Ah.T
100 0 _aAhmed Mohammad Mohi Eldin Ali
245 1 0 _aTreatment tailored therapy of diffuse large B-cell non hodgkin's lymphoma /
_cAhmed Mohammad Mohi Eldin Ali ; Supervised Hussain Mostafa Khaled , Nadia Mahmoud Mokhtar , Foaad Mohammad AbuTaleb
246 1 5 _aتحديد طريقة علاج حالات أورام الغدد الليمفاوية غير الهودجكن ذات الخلايا الكبيرة حسب كل حالة مرضية
260 _aCairo :
_bAhmed Mohammad Mohi Eldin Ali ,
_c2012
300 _a175 P. :
_bcharts ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical
520 _aCD20-positive diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of new cases of lymphoma. DLBCL is a heterogeneous disease that includes at least two prognostically important subtypes (i.e. germinal center B-cell like [GCB] and non-germinal center B-cell like [non-GCB]). These subtypes initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining
530 _aIssued also as CD
653 4 _aCD20-positive diffuse large B-cell lymphoma
653 4 _aR-CHOP
653 4 _aRituximab
700 0 _aFoaad Mohammad Abutaleb ,
_eSupervisor
700 0 _aHussain Mostafa Khaled ,
_eSupervisor
700 0 _aNadia Mahmoud Mokhtar ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c41176
_d41176